Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Watanabe K, Maeda S, Yokoe T, Imamura CK, Matsumoto K, Iwasa T, Chiba Y, Takiguchi D, Takano T. Sakai H, et al. Among authors: maeda s. BMJ Open. 2023 Apr 3;13(4):e070304. doi: 10.1136/bmjopen-2022-070304. BMJ Open. 2023. PMID: 37012013 Free PMC article.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Study protocol for efficacy and safety of steroid-containing mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study.
Kuba S, Yamanouchi K, Matsumoto M, Maeda S, Hatachi T, Sakiko S, Kawashita Y, Morita M, Sakimura C, Inamasu E, Shibata K, Otsubo R, Yano H, Nose S, Miyamoto J, Sato S, Kanetaka K, Taniguchi H, Umeda M, Nagayasu T, Eguchi S. Kuba S, et al. Among authors: maeda s. BMJ Open. 2020 Feb 13;10(2):e033446. doi: 10.1136/bmjopen-2019-033446. BMJ Open. 2020. PMID: 32060155 Free PMC article. Clinical Trial.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: maeda s. Int J Clin Oncol. 2021 Jul;26(7):1229-1236. doi: 10.1007/s10147-021-01920-0. Epub 2021 Apr 23. Int J Clin Oncol. 2021. PMID: 33891194 Free PMC article. Clinical Trial.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: maeda s. Int J Clin Oncol. 2021 Jul;26(7):1237. doi: 10.1007/s10147-021-01940-w. Int J Clin Oncol. 2021. PMID: 34043103 Free PMC article. No abstract available.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: maeda s. Int J Clin Oncol. 2022 Nov;27(11):1793. doi: 10.1007/s10147-022-02237-2. Int J Clin Oncol. 2022. PMID: 36166110 Free PMC article. No abstract available.
EFFICACY AND SAFETY OF A DEXAMETHASONE-BASED MOUTHWASH TO PREVENT CHEMOTHERAPY-INDUCED STOMATITIS IN WOMEN WITH BREAST CANCER: A MULTICENTRE, OPEN-LABEL, RANDOMISED PHASE 2 STUDY.
Kuba S, Maeda S, Shibata K, Soutome S, Yamanouchi K, Matsumoto M, Tanaka A, Morita M, Hatachi T, Otsubo R, Yano H, Kawashita Y, Sato S, Taniguchi H, Kanetaka K, Umeda M, Nagayasu T, Eguchi S. Kuba S, et al. Among authors: maeda s. J Evid Based Dent Pract. 2023 Sep;23(3):101896. doi: 10.1016/j.jebdp.2023.101896. Epub 2023 Jun 11. J Evid Based Dent Pract. 2023. PMID: 37689451 Clinical Trial.
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.
Kuba S, Soutome S, Hagiwara Y, Kikawa Y, Iwamoto T, Sangai T, Harao M, Yamaguchi T, Taji T, Igarashi A, Kajimoto Y, Sakurai N, Yamanouchi K, Watanabe K, Maeda N, Suzuki M, Maeda S, Toh U, Ebata A, Iwakuma N, Matsunuma R, Yamaguchi M, Mukai H; CSPOR-BC. Kuba S, et al. Among authors: maeda n, maeda s. Jpn J Clin Oncol. 2024 Oct 1:hyae136. doi: 10.1093/jjco/hyae136. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39354670
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, Yano H, Mashino K, Mitsuyama S, Shimokawa M, Tamura K; Kyushu Breast Cancer Study Group. Maeda S, et al. Breast. 2017 Apr;32:66-72. doi: 10.1016/j.breast.2016.12.017. Epub 2017 Jan 3. Breast. 2017. PMID: 28056400 Clinical Trial.
4,128 results